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PURPOSE: This study aimed to evaluate the efficacy of the systemic drugs thalidomide, dapsone, colchicine, and pentoxifylline 
in the treatment of severe manifestations of RAS.
METHODS: An open, 4-year clinical trial was carried out for 21 consecutive patients with severe RAS. Initially, patients were 
given a 2-week course of prednisone to bring them to a baseline status. Simultaneously, one of the four test drugs was assigned to 
each patient to be taken for a period of 6 months. During the course of the trial, patients were switched to one of the other three 
drugs whenever side effects or a lack of satisfactory results occurred, and the 6-month limit of the treatment was then reset. 
RESULTS: The most efficient and best-tolerated drug was thalidomide, which was administered to a total of eight patients and 
resulted in complete remission in seven (87.5%). Dapsone was prescribed for a total of nine patients, of whom eight (89%) showed 
improvement in their symptoms, while five showed complete remission. Colchicine was administered to a total of ten patients, 
with benefits observed in nine (90%), of whom four showed complete remission. Pentoxyfilline was administered to a total of five 
patients, with benefits observed in three (60%), of whom one patient showed complete remission. 
CONCLUSION: The therapeutic methods used in this trial provided significant symptom relief. Patients experienced relapses of 
the lesions; however, this occurred after withdrawal of their medication during the follow-up period.
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INTRODUCTION
Recurrent aphthous stomatitis (RAS) is a common oral 
inflammatory disease characterized by painful recurrent 
ulcerations of the oral mucosa.1-3 RAS shows no predilection 
for sex, and it seems to be more common among white 
individuals. There is some evidence that the disease has 
a higher prevalence in younger adults, decreasing in both 
incidence and severity with age.2-5 The cause of RAS remains 
unknown, but there is growing evidence for an immunogenic 
basis for its development.3,6,7
RAS occurs in three clinical presentations: minor, major, 
and herpetiform. Minor RAS is the most common form, and 
it is characterized by shallow, well-defined ulcers of less 
than 1 cm in diameter surrounded by an erythematous halo. 
These ulcers heal in 7–14 days without scarring. Major RAS 
is less common, but more severe than the minor form. The 
ulcers are larger and deeper, with a raised irregular border, 
and they frequently exceed 1 cm in size. Major RAS can 
last for weeks to months, and usually heals with scarring. 
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Herpetiform RAS is the rarest form of the disease, and it 
manifests as clusters of 10–100 small ulcers of 1–3 mm in 
diameter, which tend to coalesce into large ulcers and follow 
a clinical course similar to that of minor RAS (healing 
without scarring).1,8-10 
A diagnosis of RAS is almost invariably established on 
the basis of the patient’s clinical history and presentation 
of the lesions.1,2 Although histological examination is not 
in itself sufficient for a definitive diagnosis of RAS, it 
can aid in the differential diagnosis by eliminating other 
diseases that may resemble RAS clinically, including 
erosive oral lichen planus, vesiculobullous diseases, 
and oral cancer. Herpetiform RAS can be distinguished 
from intra-oral herpetic lesions via exfoliative cytology 
techniques and clinical features (e.g., herpetic, recurrent 
oral lesions usually affect keratinized oral mucosa, the 
gingival or hard palate areas, and are preceded by vesicles). 
A detailed clinical history is also important in each case of 
RAS to exclude other diseases that can present aphthous-
like lesions but cannot be differentiated from RAS based 
on histology. These include Behcet’s syndrome, Crohn’s 
disease, human immunodeficiency virus (HIV) infection, 
and neutropenia.1,10-13
There have been many attempts over the years to find 
an effective treatment for RAS. Since the etiology of RAS 
remains unknown, its treatment consists of therapeutic 
measures to suppress the symptoms rather than bringing 
about a definitive cure. The therapeutic choice depends on 
the severity of the disease, including the frequency of ulcer 
recurrence, the number of ulcers present, their location and 
duration, and the level of associated orofacial pain. Patients 
with light-to-moderate symptoms and infrequent ulcers may 
only require palliative therapy for pain.8 Cases of severe 
RAS, those with painful ulcers, and those that show a high 
frequency of recurrence usually require systemic therapy. 
The use of immunosuppressive and anti-inflammatory drugs 
has demonstrated varying degrees of success in severe cases 
of RAS. Drugs commonly used include corticosteroids, 
dapsone, colchicine, thalidomide, pentoxifylline, low-dose 
interferon-α, and levamisole.14-17
The purpose of the present investigation was to evaluate 
the clinical response to systemic drugs in the treatment of 
patients with severe RAS.
METHODS
Patient selection. Patients were selected for this 
study based on a severe clinical course of RAS, i.e., with 
multiple episodes of ulcers monthly. Patients with any 
hematologic disease, Behcet’s syndrome, Crohn’s disease, 
HIV infection or Reiter’s syndrome, either initially or as a 
later development, were not included in the study. Patients 
whose oral ulcerations could be associated with a drug 
reaction were also excluded. 
Diagnosis of RAS. Diagnosis was made based on 
the clinical presentation of lesions, as described in the 
Introduction. Histological and direct immunofluorescence 
examination was available when the clinical diagnosis 
was uncertain and was used mainly for differentiation 
from vesiculobullous diseases. A blood-cell count with 
determination of hemoglobin concentration, coupled with 
measurements of glucose-6-phosphate dehydrogenase 
(G6PD), glycemia, and liver enzyme levels was performed 
before the trial and twice a month during treatment for all 
patients. 
Patients. During the period between 2002 and 2005, 
32 consecutive patients were referred to the Clinic of Oral 
Diagnosis, Division of Dermatology, University of São 
Paulo, and subsequently diagnosed as having severe clinical 
manifestations of RAS. Later, five of the patients were 
found to have one of the aforementioned systemic diseases 
(one patient with HIV infection, one with leukemia, two 
with anemia, and one with Behcet’s syndrome), and thus 
their data was excluded from the study. The remaining 27 
patients were enrolled in the treatment protocol. This study 
was approved by the hospital’s Committee on Ethics, and 
informed consent was obtained from all participants. 
Treatment protocol. Before entering the study, patients 
were informed about the trial, the medications and their 
possible side effects. A clinical history concerning the ulcer 
type, size, number, recurrence, healing time, and symptoms 
were recorded for each patient. Initially, patients were given 
systemic prednisone for a 2-week period, starting with 
0.5 mg/kg/day as a single dose in the morning, which was 
reduced after 1 week to half the initial dose. Simultaneously, 
one of the four test drugs – namely thalidomide, dapsone, 
colchicine, or pentoxifylline – was assigned to each patient, 
keeping the proportion of assignments as equal as possible 
under the conditions that thalidomide was not prescribed 
for fertile women, while dapsone was not prescribed for 
patients with low levels of G6PD and pentoxifylline was 
only prescribed for patients who could afford it, since it was 
the only drug that could not be supplied free of charge by 
the hospital. After withdrawing the prednisone, the assigned 
drug was maintained for 6 months, unless adverse side 
effects or unsatisfactory results occurred. In either of these 
cases, the patient was switched to one of the other three 
drugs following the same safety criteria described above. 
The drugs and dosages employed are shown in table 1.
Evaluation and follow-up. Patients were evaluated at 15-
day intervals during the period of medication usage. At each 
visit, data regarding clinical status (benefits or side effects) 
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were recorded, as well as compliance with the treatment. 
Any time that a drug had to be replaced with an alternative 
drug, the 6-month time limit for using the medication was 
reset. The criteria for drug efficacy were mainly based on 
the potential to prevent relapses and/or reduce symptoms, 
numbers of ulcers, and healing time. Drug efficacy was 
classified as excellent, moderate, mild, or no response as 
follows: excellent – patient with no relapses; moderate – 
patient showing relapses but with decreasing frequency, less 
lesions per cycle, and alleviated symptoms; mild – relief of 
symptoms only; no response – no improvement observed or 
reported. After withdrawal of the medication, patients were 
followed for a period ranging from 6 to 12 months.
RESULTS
Of the 27 patients, six stopped showing up for treatment, 
and the data for these individuals were not used. Therefore, 
this study was effectively conducted for 21 patients (nine 
male and 12 female, mean age of 35.5 years). Six presented 
with major-type RAS, while 15 presented with minor types. 
No patients presented with herpetiform-type RAS. 
Biopsy for histological and direct immunofluorescence 
examination was performed for four patients in order 
to exclude other diseases. Both exams provided non-
specific findings: the histological features consisted 
predominantly of lymphocytes and neutrophils, and the 
results of the immunofluorescence technique were non-
reactive in all cases. Three female patients presented 
with systemic diseases: two were hypertensive and one 
had hypothyroidism. Only one patient was a smoker. The 
characteristics of the patients are shown in table 2.
Initial drug assignments are shown in table 3. Eleven 
patients were switched to alternative drugs. At the end 
of this trial, the percentage of each drug evaluated was 
higher than at its initial assignment, as shown in table 4, 
which summarizes the efficacy of all drugs tested. The 
most efficient and best-tolerated drug was thalidomide, 
since patients who used this drug showed an excellent 
Table 1 - Therapeutic schedule 
Drugs Dosage
Prednisone
Byyny [33] 
0.5 mg/kg/day for 7 days
 half of the dose for 7 days 
Thalidomide
Bonnetblanc et al.[29]
100 mg/day 
Dapsone 
Ahmed et al.[30] 
25 mg/day for 3 days
50 mg/day for 3 days
75 mg/day for 3 days
100 mg/day maintenance dose
Colchicine
Ruah et al.[11]
0.5 mg/day for 7 days
1.0 mg/day for 7 days
1.5 mg/day maintenance dose
Pentoxifylline
Pizarro et al.[22]
400 mg 3 times a day
Table 2 - Characteristics of the patients (n = 21)
Characteristics Male Female Total
Age range (mean) years 10–58 (29.9) 13–78 (41.9) 10–78 (35.5)
Caucasian 9 10 19
Non-caucasian 0 2 2
Familial history of RAS 4 7 11
Lesions per cycle 
    1
    2 to 3
    > 3
0
2
7
0
4
8
0
6
15
Healing time 
    7 to 10 days
    11 to 20 days
    21 to 30 days
4
0
5
10
0
2
14
0
7
Type of ulcer
    Major
    Minor
    Herpetiform
5
4
0
1
11
0
6
15
0
Systemic diseases
    Yes
    No
0
9
3 
9
3
18
Medications
    Anti-hypertensives 
    Cardiac drugs
    Thyroid drugs 
0
0
0
2
1
1
2
1
1
n = number of patients
Table 3 - Drug assignments (n = 21)
Drugs Initial 
Assignments
Switched to
Thalidomide Dapsone Colchicine Pentoxifylline
Thalidomide 7 – 1 1 –
Dapsone 8 – – 3 –
Colchicine 5 1 – – 4
Pentoxifylline 1 – – 1 –
n = number of patients
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response to therapy and did not develop any significant side 
effects. Dapsone, despite presenting good results, had to be 
discontinued for most of the patients (six out of nine) due to 
its adverse side effects. Colchicine and pentoxifylline also 
provided good results with few side effects; nevertheless, 
pentoxifylline was used by only five patients due to its 
financial cost. The side effects experienced were categorized 
into three types: mild – minor gastrointestinal pain and 
nausea; moderate – dizziness, fatigue, diarrhea, lethargy, and 
headache; or severe – hemolysis, jaundice, and decreased 
hemoglobin level. The mean time for use of each drug and 
the patient side effects are shown in table 5. 
All patients presented relapses after discontinuing 
medication during the follow-up period. Recurrences 
occurred from 2 weeks up to 9 months, but most of the 
patients experienced relapses within a few weeks after the 
medication was withdrawn.
DISCUSSION
Treatment of RAS remains a great challenge. Different 
kinds of treatment have been attempted over the years, yet no 
specific management has been established as being the most 
appropriate.18 RAS affects patients differently and, in some 
cases, may cause severe pain and interfere with one’s day-to-
day life. The present study dealt with patients suffering from 
the severe form of RAS, and therefore received systemic 
medication.
Each of the four drugs compared in this trial was 
previously tested separately in other studies.18-26 The anti-
inflammatory and immunological properties of these 
drugs enable them to reduce or prevent the development 
of RAS. Dapsone appears to inhibit the migration of 
polymorphonuclear leukocytes (PMNs) by inhibiting 
lysosomal enzyme activity and interfering with the 
cellular response to chemotactic stimuli.27,28 Colchicine 
appears to depolymerize the microtubular proteins of 
inflammatory cells, inhibiting chemotaxis, mobilization, 
adhesiveness, and lysosomal degranulation11. Thalidomide 
and pentoxifylline present immunomodulatory and anti-
inflammatory properties, and inhibit the production of tumor 
necrosis factor alpha (TNFα).15,18,22,29
A corticosteroid (prednisone) was prescribed for all 
patients at the beginning of the trial in order to dampen the 
RAS bout in course. This procedure was carried out to obtain 
a baseline for comparison of the results and to provide relief 
of symptoms for the patients. The short-term prescription 
of a corticosteroid (0.5mg/kg/day/1week, followed by half 
this dosage for another week) did not cause any significant 
adverse side effects and was valuable in decreasing patient 
discomfort. This initial course with a systemic corticosteroid 
was important for halting bouts of RAS and for patients’ 
compliance with the trial. 
Thalidomide was the most effective drug tested in this 
trial. It was administered to a total of eight patients for a 
time period ranging from 3 to 6 months (mean, 4.8 months). 
Table 4 - Efficacy of the drugs prescribed in the trial 
Drugs Initial assignments 
(n = 21)
Total assignments 
throughout trial 
Evaluation
Excellent Moderate Mild No Response
Thalidomide 7 8 7 0 0 1
Dapsone 8 9 5 3 0 1
Colchicine 5 10 4 4 1 1
Pentoxifylline 1 5 1 2 0 2
n = number of patients
Table 5 - Side effects associated with the drugs
Thalidomide Dapsone Colchicine Pentoxifylline
Assignments 8 9 10 5
Period of administration 
(mean)
3 to 6 months 
(4.8 months) 
1 to 6 months 
(4.2 months)
2 to 6 months 
(4.8 months) 
1 to 6 months 
(3.0 months)
Severe side effects 0 3 (33.3%) 0 0
Moderate side effects 0 3 (33.3%) 0 1 (83.3%)
Mild side effects 1 (12.5%) 0 3 (30%) 0
No side effects 7 (87.5%) 3 (33.3%) 7 (70%) 4 (16.7%)
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It worked very well in most cases, seven (87.5%) of which 
resulted in complete remission of RAS; one patient presented 
no response. The percentage of complete remission obtained 
for our patients was much higher than that reported by 
other authors, namely Grinspan et al.24 (34%) and Revuz et 
al.20 (48%), for which the number of patients treated with 
thalidomide (40 and 73, respectively) was higher than that in 
the present study. In terms of side effects, Revuz et al.20 found 
a high percentage of adverse side effects with thalidomide 
use, mainly drowsiness (75%) and constipation (40%). 
Similar side effects were also observed by Bonnetblanc et 
al.29 (64%) and Grinspan et al.24 (48%). In the present study, 
only one (12.5%) patient complained of slight drowsiness 
during the thalidomide course. 
Dapsone was given to a total of nine patients for lengths 
of time ranging from 1 to 6 months (mean, 4.2 months). 
Eight of these patients (89%) showed excellent-to-moderate 
improvement of their symptoms. This result was somewhat 
better than the results obtained by Handfield-Jones et al.19, 
who reported improvement in 50% of their patients using 
the same protocol and dosage as those used in our trial 
(100 mg/day). These authors did not mention side effects 
with the dapsone use. Dapsone had to be discontinued 
for six of our patients due to its moderate-to-severe side 
effects. In three of these patients, anemia, hemolysis, and 
jaundice occurred early in the course of medication, and 
the patients did not receive any other systemic medication 
until they had completely recovered to a healthy clinical 
condition. Other authors using dapsone for ulcerative 
mucosal diseases other than RAS have reported similar side 
effects, although these were less severe and more delayed 
in their onset.27,30
During the course of the trial, colchicine was prescribed 
to a total of ten patients for a period of time ranging from 
2 to 6 months (mean, 4.8 months). Benefits were obtained 
with colchicine in nine patients (90%), among which 
four experienced complete remission of lesions, four 
demonstrated moderate improvement, and one experienced 
only a mild benefit. Efficacy with the use of colchicine for 
treatment of RAS has also been reported by other authors21,25, 
with improvement ranging from 63 to 71% of the cases. In 
one of these studies25, patients were followed for as long as 
4.7 years and, at the end of that period, 37% of the patients 
(without medication) still maintained a better clinical status 
compared with the period before treatment. Side effects with 
colchicine have been observed in many studies11,21,31,32, and 
are mainly characterized by gastrointestinal disturbances 
(e.g., diarrhea and nausea) and paresthesia of the lower 
extremities. Ruah et al.11 reported that the continuous use of 
colchicine could lead to the development of neuropathy and 
myopathy. In the present study, three patients complained of 
some discomfort (diarrhea), which was easily controlled by 
slightly lowering their dosage.
Pentoxifylline was prescribed for only five patients 
since the cost of this medication impeded its availability 
in the present trial. Pentoxifylline was used for a period 
ranging from 1 to 6 months (mean, 3.0 months). In two 
patients (40%), a moderate improvement was observed 
(shorter healing time, less severe symptoms, and a lower 
recurrence rate), while one patient (20%) presented 
with complete remission and two others experienced no 
benefit. These results were in agreement with those of 
Pizarro et al.22 and Chandrasekhar et al.15 , who obtained 
excellent-to-satisfactory results with pentoxifylline in 50 
to 60% of their patients. Even better results were obtained 
by Wahba-Yahva23, who reported stable remission in all 
cases (six patients). Side effects were seldom reported by 
patients in those studies. In the present study, the patients 
also presented few side effects, with only one patient 
manifesting dizziness and nausea and for whom the 
medication was discontinued. 
Regarding the effect of the drugs in preventing RAS 
recurrences after their withdrawal, dapsone was found 
to yield the best results. Of the patients who reported 
benefits with dapsone, three remained ulcer free without 
medication for up to 9 months. Colchicine apparently 
did not protect patients against new bouts of RAS after 
withdrawal, since recurrences occurred within 2 to 3 weeks 
after drug discontinuation. Similar results were observed 
with pentoxifylline, as just one patient remained ulcer 
free for a 5-month period of time after drug withdrawal. 
As for thalidomide, patients experienced no recurrences 
for a 2-week to 4-month period after its withdrawal. Of 
note, three patients who had their th alidomide prescription 
discontinued during the course of therapy due to a temporary 
interruption in hospital supply experienced a rapid worsening 
of their clinical status, which was not improved by any other 
drug used in this trial. These patients were placed back on 
thalidomide as soon as it became available and regained the 
clinical status they presented before the interruption. It is 
also important to mention that, five of the six patients with 
major-type RAS, benefited from the treatment protocol with 
thalidomide, thus reinforcing the effectiveness of this drug 
for RAS treatment. 
CONCLUSION
The therapeutic methods used in this trial were able to 
provide significant relief of symptoms for as long as the drug 
was administered. Relapses of the lesions after withdrawal of 
the medication, however, were observed during the follow-up 
period. Thalidomide provided the best results in our trial, but 
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this drug presents problems with regard to accessibility, and 
its use is precluded for fertile women. Dapsone produced 
benefits, but also resulted in severe adverse side effects. 
Pentoxifylline was moderately effective, although it was not 
properly tested in this trial. Colchicine demonstrated good 
results and was well tolerated by the patients. 
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